Literature DB >> 16230464

Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva.

Joseph A Kitterman1, Sharon Kantanie, David M Rocke, Frederick S Kaplan.   

Abstract

BACKGROUND: Little is known about diagnostic errors for a disease worldwide. Such errors could alter the disease's natural history, especially if unwarranted interventions cause irreversible harm. Fibrodysplasia ossificans progressiva (FOP), a rare, autosomal dominant genetic disease characterized by episodes of permanent heterotopic ossification of soft tissues, occurs worldwide without racial, ethnic, or geographic predilection. There is no effective treatment, and soft-tissue trauma (eg, biopsies, surgical procedures, intramuscular injections, or mandibular blocks for dental procedures) and viral illnesses are likely to induce episodes of rapidly progressive heterotopic ossification, with resultant permanent loss of motion in the affected area. Accurate diagnoses can be made on the basis of the clinical findings of tumor-like swellings on the head, neck, back, or shoulders and characteristic short great toes with hallux valgus-like malformations and missing interphalangeal joints. On the basis of conversations with numerous individuals with FOP, we suspected that diagnostic errors with FOP are common and often associated with inappropriate and harmful diagnostic and therapeutic procedures.
OBJECTIVE: To document the frequency of diagnostic errors with FOP and complications resulting from misdiagnoses.
DESIGN: A questionnaire requesting detailed demographic, diagnostic, and treatment information was sent to all 269 patient-members of the International FOP Association; the sampling frame included > 90% of all known FOP patients worldwide. We received 138 replies (51% response) from 25 countries. The age range was 2 to 71 years; there were 78 female subjects and 60 male subjects. In addition, to assess the availability and adequacy of information about FOP, we reviewed 184 English-language textbooks in relevant specialties published in the past 20 years.
RESULTS: Incorrect diagnoses were given initially to 87% of individuals with FOP. This astonishing rate of diagnostic errors occurred worldwide, regardless of ethnicity, geographic background, or misdiagnosing physician's specialty. The most common incorrect diagnosis was cancer (32%). The mean period from the onset of symptoms to correct diagnosis was 4.1 years, and the median number of physicians consulted before the correct diagnosis of FOP was 6. For 67% of patients, unnecessary invasive procedures (biopsies) were performed; 68% received inappropriate therapies. Forty-nine percent of all patients reported permanent loss of mobility resulting from invasive medical interventions that caused posttraumatic ossification. Notably, only 8% of the 184 textbooks that were reviewed contained adequate descriptions of FOP, including the caution that trauma can accelerate the process of heterotopic ossification.
CONCLUSIONS: Diagnostic errors and inappropriate medical procedures, which may lead to permanent harm, can alter the natural history of a disease. In FOP, the astonishing rates of diagnostic errors and inappropriate invasive medical procedures likely result from lack of physician awareness because of failure of information transfer.

Entities:  

Mesh:

Year:  2005        PMID: 16230464     DOI: 10.1542/peds.2005-0469

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  79 in total

1.  Multiple palpable nodules: do not miss the great toes.

Authors:  Mamta Sengar; Vishesh Jain; Kalpana Bansal; Anup Mohta
Journal:  Indian J Pediatr       Date:  2013-07-20       Impact factor: 1.967

2.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

3.  Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva.

Authors:  Nathalie Bravenboer; Dimitra Micha; James T Triffit; Alex N Bullock; Roberto Ravazollo; Renata Bocciardi; Maja di Rocco; J Coen Netelenbos; Peter Ten Dijke; Gonzalo Sánchez-Duffhues; Fred S Kaplan; Eileen M Shore; Robert J Pignolo; Petra Seemann; Francesc Ventura; Genevieve Beaujat; Elizabeth M W Eekhoff; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2015-01-21       Impact factor: 4.246

4.  Fibrodysplasia ossificans progressiva: a case report.

Authors:  Richard O Baidoo; Makafui S Dayie
Journal:  Ghana Med J       Date:  2016-12

Review 5.  Cellular and morphological aspects of fibrodysplasia ossificans progressiva. Lessons of formation, repair, and bone bioengineering.

Authors:  Anderson Martelli; Arnaldo Rodrigues Santos
Journal:  Organogenesis       Date:  2014-10-31       Impact factor: 2.500

6.  Pregnancy in fibrodysplasia ossificans progressiva.

Authors:  Javaid A Muglu; Aditya Garg; T Pandiarajan; Eileen M Shore; Frederick S Kaplan; Dhiraj Uchil; Malcolm J Dickson
Journal:  Obstet Med       Date:  2011-12-08

7.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

8.  The stone man disease: fibrodysplasia ossificans progressiva: imaging revisited.

Authors:  Amit Kumar Verma; Pallavi Aga; Shailesh Kumar Singh; Ragini Singh
Journal:  BMJ Case Rep       Date:  2012-07-25

9.  PET/CT of fibrodysplasia ossificans progressiva.

Authors:  Robert Kulwin; Larry A Binkovitz
Journal:  Pediatr Radiol       Date:  2009-05-15

10.  An unusual case of rapidly progressive contractures: Case report and brief review.

Authors:  R Subasree; Samhita Panda; Pramod Kumar Pal; S Ravishankar
Journal:  Ann Indian Acad Neurol       Date:  2008-04       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.